Recent stock performance context for KalVista Pharmaceuticals

KalVista Pharmaceuticals (KALV) has drawn fresh attention after a strong share price move, with the stock up about 31% over the past month and roughly 79% over the past 3 months.

That recent surge sits on top of a much stronger long-term picture, with a 1-year total shareholder return of 124.06% and a 3-year total shareholder return of 153.85%, signalling firm upward momentum around KalVista Pharmaceuticals.

If rapid price moves in biotech interest you, this is a good moment to broaden your watchlist and check out 32 healthcare AI stocks

With KalVista Pharmaceuticals now trading close to its analyst price target and carrying an implied intrinsic discount, the key question is whether the recent surge still leaves mispricing on the table or whether markets already reflect future growth.

Most Popular Narrative: 13.8% Undervalued

KalVista Pharmaceuticals' most followed narrative points to a fair value of $31.00 per share, compared with the latest close at $26.73, putting the current rally in a broader context.

Early EKTERLY uptake in high burden hereditary angioedema patients, reflected in 937 U.S. start forms within roughly 4 months and refill patterns more frequent than historical injectable on demand therapies, points to a treatment shift that could support higher on demand prescription volumes and revenue per patient.

Want to understand why this fair value sits above today’s price? The narrative leans heavily on rapid revenue expansion, margin improvement and a rich future earnings multiple. The real story is in how those pieces fit together.

Result: Fair Value of $31.00 (UNDERVALUED)

However, there is still a risk that EKTERLY demand normalizes below early high burden usage and that payer limits or step requirements constrain future paid prescription volumes.

Next Steps

With sentiment split between strong upside potential and clear risks, this is a moment to look through the numbers yourself and decide quickly where you stand. You can start with 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your goals even better, so put a few strong alternatives on your radar today.

• Target higher quality opportunities by scanning for companies trading below estimated value with solid fundamentals using the 51 high quality undervalued stocks.
• Prioritize income potential by reviewing companies offering yields above 5% and consistent payouts through the 13 dividend fortresses.
• Reduce surprise risk by focusing on companies with stronger balance sheets and healthier fundamentals via the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.